About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their ...

Researchers in Australia use COVID-era mRNA technology to expose hidden HIV in white blood cells, offering hope for a future ...

Physicians and their patients report that engagement in an HIV-based community rivals drug effectiveness in the ... strategy to engage at-risk and HIV-positive young men in prevention and ...

A positive effect that COVID-19 vaccines would have on the human body has been discovered. The technology used in these vaccines could also lead scientists to a cure for the human ...

including long-acting injectable products that release drugs over weeks or months. Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral ...

including the general HIV-positive population, as well as for PrEP. ViiV, meanwhile, is working on a self-injectable formulation of its drug and is investigating new versions that could offer ...

Children between the ages of 10 to 14 years are testing positive for HIV and this is concerning. This stat has been revealed ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

The medication, Lenacapavir, is said to have shown exceptional promise in clinical trials, and some of the research is being conducted here in Houston.

twice-yearly injectable medication that experts say could revolutionize HIV prevention. The drug, Lenacapavir, has shown exceptional promise in clinical trials, including research conducted in ...

A new study found that implementing a specialty pharmacy program at St. Jude Children’s Research Hospital helped more young HIV patients achieve medication adherence and undetectable viral loads.

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...